A phase I study of the combination of ro4929097 and cediranib in patients with advanced solid tumours (PJC-004/NCI 8503)

S Sahebjam, P L Bedard, V Castonguay, Z Chen, M Reedijk, G Liu, B Cohen, W-J Zhang, B Clarke, T Zhang, S Kamel-Reid, H Chen, S P Ivy, A R A Razak, A M Oza, E X Chen, H W Hirte, A McGarrity, L Wang, L L Siu and S J Hotte

1Princess Margaret Hospital, Toronto, ON M5G 2M9, Canada; 2National Cancer Institute, Bethesda, MD, 20852-7426, USA and 3Juravinski Cancer Centre, 699 Concession Street, Hamilton, ON L8V 5C2, Canada

Background: The Notch signalling pathway has been implicated in tumour initiation, progression, angiogenesis and development of resistance to vascular endothelial growth factor (VEGF) targeting, providing a rationale for the combination of RO4929097, a γ-secretase inhibitor, and cediranib, a VEGF receptor tyrosine kinase inhibitor.

Methods: Patients received escalating doses of RO4929097 (on a 3 days-on and 4 days-off schedule) in combination with cediranib (once daily). Cycle 1 was 42 days long with RO4929097 given alone for the first 3 weeks followed by the co-administration of both RO4929097 and cediranib starting from day 22. Cycle 2 and onwards were 21 days long. Soluble markers of angiogenesis were measured in plasma samples. Archival tumour specimens were assessed for expression of three different components of Notch signalling pathway and genotyping.

Results: In total, 20 patients were treated in three dose levels (DLs). The recommended phase II dose was defined as 20 mg for RO4929097 on 3 days-on and 4 days-off schedule and 30 mg daily for cediranib. The most frequent treatment-related adverse events (AEs) were diarrhoea, hypertension, fatigue and nausea. Eleven patients had a best response of stable disease and one patient achieved partial response. We did not detect any correlation between tested biomarkers of angiogenesis or the Notch pathway and treatment effect. There was no correlation between mutational status and time to treatment failure.

Conclusion: RO4929097 in combination with cediranib is generally well tolerated at the DLs tested. Preliminary evidence of antitumour efficacy with prolonged disease stabilisation in some patients with progressive malignancies warrants further clinical investigation of this treatment strategy.
that Dll4–Notch signalling promotes tumour growth by improving the structure and function of tumour vasculature (Noguera-Troise et al., 2006; Ridgway et al., 2006; Li et al., 2007).

Targeting tumour angiogenesis via inhibition of vascular endothelial growth factor (VEGF) and its receptors (VEGFRs) has been a successful strategy in the treatment of several solid malignancies. Cross-talk between Notch and VEGF pathways is a potential mechanism of developing resistance to VEGF-targeted therapies (Patel et al., 2006; Li et al., 2011; Benedito et al., 2012). In preclinical studies, the Dll4–Notch signalling has been implicated in the development of resistance to VEGF-targeted multi-kinase inhibitors and Notch pathway inhibition has been able to restore sensitivity to these agents (Li et al., 2011). In a glioblastoma xenograft mouse model, resistance to bevacizumab was abolished by a combination of γ-secretase inhibitor of the Notch pathway with bevacizumab (Li et al., 2011). Moreover, the combination of bevacizumab and a γ-secretase inhibitor synergistically inhibited tumour growth in bevacizumab-sensitive models, providing a rational base for a combination of γ-secretase inhibitor with VEGFR inhibitors in a clinical setting (Li et al., 2011). This phase I trial was initiated to evaluate the safety and tolerability, as well as antitumour activity of cediranib, a multi-kinase VEGFR inhibitor, with an inhibitor of the Notch signalling pathway, RO4929097.

Cediranib (AZD2171) is a highly potent inhibitor of VEGF signalling, with activity against all three VEGF receptors (VEGF-1, VEGFR-2 and VEGFR-3), and c-Kit (Wedge et al., 2005). In a phase I trial, cediranib at 45 mg once daily dose was well tolerated and the most frequently reported AEs were diarrhoea, dysphonia and hypertension (Dreves et al., 2007). Antitumour efficacy of cediranib has been investigated in several phase II/III trials (Batchelor et al., 2010; Campbell et al., 2012; Hoff et al., 2012; Mulders et al., 2012; Schmoll et al., 2012).

RO4929097 is a potent and selective γ-secretase small-molecule inhibitor with antitumour activity in xenograft models, including colon cancer, pancreatic carcinoma and non-small cell lung cancer (Luistro et al., 2009). In a phase I study for patients with advanced malignancies, RO4929097 was well tolerated at 270 mg on a 3 days-on 4 days-off schedule, with skin, gastrointestinal events and fatigue being the most common toxicities (Tolcher et al., 2012).

This report summarises the final data of safety, efficacy and pharmacokinetics of RO4929097 in combination with cediranib in patients with advanced solid tumours.

MATERIALS AND METHODS

Study objectives. The primary objectives of this phase I clinical trial were to evaluate the safety and tolerability of escalating doses of RO4929097 in combination with cediranib, to characterise dose-limiting toxicities (DLTs) and to determine the recommended dose for phase 2 trials (RP2D). The secondary objectives were to assess pharmacokinetic properties, pharmacodynamic effects and to make a preliminary assessment of tumour response in patients with advanced solid tumours.

Patient eligibility. Patients were eligible if they had histologically or cytologically documented advanced solid malignancy, refractory to standard therapy or for which conventional therapy was not effective. Other key eligibility criteria included: age ≥18 years; Eastern Cooperative Oncology Group performance status of ≤1; life expectancy ≥12 weeks; adequate haematological (leukocyte count ≥3000 per mcl; absolute neutrophil count ≥1500 per mcl; haemoglobin ≥9 g d l⁻¹; platelet count ≥100 000 per mcl), hepatic (total bilirubin within normal institutional limits; aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤2.5 x institutional upper limit of normal), renal (creatinine within institutional normal limit or creatinine clearance ≥60 ml min⁻¹ per 1.73 m² for patients with creatinine more than institutional normal limits) and cardiac function (left ventricular ejection fraction ≥50%); negative serum pregnancy test in women of childbearing potential. Treatment could begin >30 days after the patient’s last therapy. Key exclusion criteria included previous treatment with a γ-secretase inhibitor and/or cediranib, meningeval or untreated brain metastases, major organ dysfunction, concurrent use of medications that are strong inducers/inhibitors or substrates of CYP3A4 enzyme, QTc interval greater than or equal to 450 ms in men and 470 ms in women by Bazett’s correction and pregnancy or lactation. Previous therapy with other VEGFR tyrosine kinase inhibitors, such as sunitinib, was allowed.

Study design. This was an open-label, dose escalation phase I trial. It followed the standard 3+3 rule and no intra-patient dose escalation was allowed. Initial design of study consisted of two stages: (1) dose escalation and (2) expansion cohort, including patients with breast cancer, malignant melanoma, colorectal cancer, pancreatic cancer, renal cancer, high-grade glioma, non-small cell lung cancer, or ovarian cancer. However, accrual was terminated on 7 April 2012, after completion of three dose levels (DLs), due to discontinuation of RO4929097’s development. Patients who were felt to be deriving clinical benefit were allowed to remain on cediranib monotherapy on study. The trial was approved by all relevant institutional ethical committees.

Patients in DL-1 received RO4929097 at 10 mg and cediranib at 20 mg. At DL-2, both RO4929097 and cediranib were administered at 20 mg. At DL-3, RO4929097 and cediranib were given at 20 mg and 30 mg, respectively. The rational for starting dose of cediranib at 20 mg was based on results of other phase I trials where cediranib was administered in combination with chemotherapy or targeted agents (Goss et al., 2009; van Cuijisen et al., 2010; Trarbach et al., 2012). In these studies, the maximum-tolerated dose of cediranib was always lower than 45 mg once daily. Furthermore, because an interim analysis of the BR24 phase II clinical trial demonstrated higher rates of serious AEs when cediranib at 30 mg per day was added to carboplatin and paclitaxel, the dose of 20 mg once daily was selected as starting dose of cediranib (Goss et al., 2010). At the time of study design, there were no available data on RO4929097 in combination with other agents. However, given the issues of CYP3A4 induction as well as autoinduction by RO4929097, the starting dose of 10 mg once daily was selected for RO4929097 in combination with cediranib (Tolcher et al., 2012). Cycles of treatment consisted of 21 days except for cycle 1, which was 42 days long consisting of a 3 weeks run-in period of RO4929097 alone. RO4929097 was administered on a 3 days-on and 4 days-off schedule (days 1–3, 8–10, 15–17, 22–24, 29–31 and 36–38) in combination with cediranib once daily starting from day 22 (days 22–42). Cycle 2 and onwards were 21 days in duration and consisted of once daily cediranib with RO4929097 on days 1–3, 8–10 and 15–17 (Supplementary Appendix Figure A1). Patients were treated until disease progression, occurrence of intolerable AEs, or study withdrawal.

The doses and schedule of RO4929097 and cediranib were chosen based on good tolerability in previous single-agent phase I trials of patients with advanced solid tumours (Dreves et al., 2007; Tolcher et al., 2012).

Safety. The safety and tolerability of combination regimen were assessed by collecting the incidence and severity of AEs, using the National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.0.

The DLT was assessed during the first cycle (42 days) and defined as a treatment-related event meeting the following criteria: grade 4 neutropenia lasting ≥7 days, febrile neutropenia (absolute neutrophil count <1.0 x 10⁹ per l and fever ≥38.5°C), grade 4 thrombocytopenia or thrombocytopenic bleeding (i.e., platelet count <50 x 10⁹ per l and associated with clinically significant
bleeding), grade 4 diarrhoea, grade 3 diarrhoea lasting >72 h, despite medical management, any other non-haematologic grade 3 or 4 treatment-related toxicity lasting >72 h, despite appropriate medical therapy, failure to receive 80% of the planned dose of RO4929097 or cediranib, and inability to resume dosing for cycle 2 within 14 days due to treatment-related toxicity.

**Pharmacokinetic assessment.** To detect potential drug interaction, blood samples for pharmacokinetic evaluation of RO4929097 were serially collected on days 1, 10 and 22 of cycle 1 before dosing and at 0.5, 1, 2, 4, 6 and 24 h after dosing. Blood samples for pharmacokinetic analysis of cediranib were collected on day 22 of cycle 1 before dosing and at 0.5, 1, 2, 4, 6 and 24 h after dosing. The unbound RO4929097 samples were obtained by filtrating plasma samples using Amico Centrifree Microporation devices (Millipore Corp., Bedford, MA, USA) (Zhang et al., 2008). Concentrations of RO4929097, total and unbound, and cediranib were determined using validated HPLC tandem mass spectrometry methods. Pharmacokinetic parameters were calculated by non-parametric methods using WinNonlin (Version 5.3; Pharsight Corp., Sunnyvale, CA, USA).

**Pharmacodynamic assessment.**

**Circulating biomarker evaluation.** Soluble markers of angiogenesis were measured in blood samples collected before dosing on day 1 of cycle 1, day 22 of cycle 1 and day 1 of cycle 2. Plasma analysis was carried out for circulating VEGF-A, VEGF-B, VEGF-C, basic fibroblast growth factor, stromal cell-derived (SDF)-1 alpha factor, interleukin-6, and interleukin-8 levels using enzyme-linked immunosorbent assay kit from R&D System (Minneapolis, MN, USA). The assays were performed according to manufacturer’s instructions. A triplicate was performed when the duplicate values differed by more than 15%. If at least two results were not within 15% of each other, results were discarded.

**Archival tumour biomarker.** Archival tumour specimens were assessed for expression of three different components of the Notch signalling pathway: Jagged-1, Notch-3 receptor and Notch-1 intracellular domain (NICD). Our initial plan was to test a panel of Notch pathway components. However, because of the discontinuation of treatment and limited number of patients, we selected to study the abovementioned three key biomarkers. Overexpression and prognostic significance of these markers have been reported in multiple studies (Reedijk et al., 2005; Dickson et al., 2007; Lin et al., 2010; Wu et al., 2011). Immunohistochemistry was performed using standard techniques. Anti-NICD (Cell Signaling #2421; Danvers, MA, USA) and anti-Notch-3 (Santa Cruz Biotechnologies #sc-5593; Santa Cruz, CA, USA) staining was performed using VECTASTAIN ABC rabbit IgG kit (Vector Labs #PK-4001; Burlingame, CA, USA). For anti-Jagged-1 (R&D Systems #AF1277; Abingdon, UK) staining, Cell and Tissue Goat IgG Staining kit (R&D Systems #CTS008; Abingdon, UK) was utilised. All immunohistochemistry was performed using Shandon Sequenza immunostaining cover plates (Fisher #7219590) and Peroxidase Substrate Kit, DAB (Vector Labs #SK-4100).

Expressions of these three markers were quantified by a pathologist (B.C.) who was blinded to the clinical outcome data and by using the Allred score (Allred et al., 1998; Dickson et al., 2007).

In patients with available formalin-fixed paraffin-embedded (FFPE) specimens with sufficient DNA, genotyping was performed with either Sequenom PMH v1.0 panel, a customised Sequenom MassArray for solid tumours that includes 280 mutations in 23 genes, or MiSeq TruSeq Amplicon Cancer Panel.

**RESULTS**

**Patient characteristics.** From 31 May 2010 through 6 November 2012, 20 patients were recruited at two centres (Princess Margaret Cancer Center and Juravinski Cancer Center), with baseline characteristics as shown in Table 1. Three DLs were evaluated (Table 2). As of data cut-off date on 6 November 2012, patients received a median number of three cycles (range 1–28+). At the time of this report, two patients are still receiving therapy.

**Safety.** All 20 treated patients were evaluable for non-haematologic and haematologic toxicities. Combination of RO4929097 with cediranib was generally well tolerated. The most frequent treatment-related AEs (occurring in greater than 30% of patients) of all grades and those of grades 3 or higher are described in Table 3. The most common treatment-related AEs during cycle 1 are presented in Supplementary Appendix Table A1. Briefly, the most frequently reported treatment-related AEs were diarrhoea, hypertension, fatigue, nausea, headache, hypothyroidism,

---

**Table 1. Baseline demographics and patient characteristics (N=20)**

| Characteristic             | Median | Range |
|---------------------------|--------|-------|
| Age, years                | 54     | 18-87 |
| Gender, n (%)             |        |       |
| Male                      | 10 (50)|       |
| Female                    | 10 (50)|       |
| ECOG score, n (%)         |        |       |
| 0                         | 4 (20) |       |
| 1                         | 16 (80) |     |
| Tumour type, n (%)        |        |       |
| Colorectal                | 6 (30) |       |
| Renal cell                | 3 (15) |       |
| Leiomyosarcoma            | 3 (15) |       |
| Other                     | 8 (40) |       |
| Previous therapies        |        |       |
| Systemic therapy          | 19 (95)|       |
| Antiangiogenic agents     | 11 (55)|       |
| Radiotherapy              | 12 (60)|       |

**Abbreviation:** ECOG = Eastern Cooperative Oncology Group.

**Table 2. Dose level evaluated and encountered DLTs**

| Dose level | Drugs                        | Number of patients | Number of observed DLTs | DLT description          |
|------------|------------------------------|--------------------|-------------------------|--------------------------|
| 1          | RO4929097 10 mg, Cediranib 20 mg | 7                  | 1                       | Grade 3 hypertension     |
| 2          | RO4929097 20 mg, Cediranib 20 mg | 7                  | 1                       | Grade 4 elevation of AST and grade 3 elevation of ALT |
| 3          | RO4929097 20 mg, Cediranib 30 mg | 6                  | 0                       |                          |

**Abbreviations:** ALT = alanine aminotransferase; AST = aspartate aminotransferase; DLT = dose-limiting toxicity.
hypophosphatemia, increased ALT, and elevated AST. The majority of these were grade 1 or 2 events, but 4 (20%) patients experienced grade 3 AEs consisting of hypertension (n = 3) and hypophosphatemia (n = 1). Both conditions were reversible with temporary discontinuation of study drugs. One patient experienced grade 4 elevation of AST and grade 3 elevation of ALT as discussed below.

Two patients experienced DLTs. In DL-1, one patient experienced grade 3 hypertension on day 38 of cycle 1, which was reversible after temporary discontinuation of treatment. The patient tolerated retreatment with RO4929097 at 10 mg per day dose and a reduced dose of cediranib (15 mg). At DL-2, one patient experienced grade 4 elevation of AST and grade 3 elevation of ALT on day 36 of cycle 1, which was resolved after permanent discontinuation of treatment.

Pharmacokinetics. In our study, pharmacokinetic parameters of cediranib were similar to the previously observed monotherapy data (Drevs et al., 2007). Pharmacokinetic analysis of RO4929097 showed similar Cmax and AUCt as phase I monotherapy study.

| Drug-related AE (%) | Grade | Dose level | Cediranib | RO4929097 | Cediranib | RO4929097 | Cediranib | RO4929097 |
|---------------------|-------|------------|-----------|------------|-----------|------------|-----------|------------|
|                     | All   | 1 (n = 7)  | 2 (n = 7) | 3 (n = 6)  |           |            |           |            |
| Diarrhoea           | All   | 3–4        | 6 (86%)   | 0 (0%)     | 3 (43%)   | 0 (0%)     | 4 (66%)   | 0 (0%)     |
| Hypertension        | All   | 3–4        | 6 (86%)   | 2 (28%)    | 3 (43%)   | 0 (0%)     | 2 (28%)   | 4 (66%)    |
| Fatigue             | All   | 3–4        | 3 (43%)   | 3 (43%)    | 3 (43%)   | 0 (0%)     | 4 (66%)   | 0 (0%)     |
| Nausea              | All   | 3–4        | 3 (43%)   | 4 (57%)    | 3 (43%)   | 0 (0%)     | 4 (66%)   | 0 (0%)     |
| Hypothyroidism      | All   | 3–4        | 3 (43%)   | 2 (28%)    | 2 (28%)   | 0 (0%)     | 3 (50%)   | 0 (0%)     |
| Headache            | All   | 3–4        | 4 (57%)   | 1 (14%)    | 1 (14%)   | 0 (0%)     | 3 (66%)   | 0 (0%)     |
| Hypophosphatemia    | All   | 3–4        | 3 (43%)   | 2 (28%)    | 3 (43%)   | 0 (0%)     | 2 (33%)   | 0 (0%)     |
| Increased ALT       | All   | 3–4        | 2 (28%)   | 1 (14%)    | 3 (50%)   | 0 (0%)     | 3 (50%)   | 0 (0%)     |
| Increased AST       | All   | 3–4        | 0 (0%)    | 5 (71%)    | 2 (33%)   | 0 (0%)     | 2 (33%)   | 0 (0%)     |

| Abbreviations: ALT = alanine aminotransferase; AST = aspartate aminotransferase. |

| Table 3. Common treatment related adverse events |
|-----------------------------------------------|
| Dose level | Cediranib 20 mg | RO4929097 10 mg | Cediranib 20 mg | RO4929097 20 mg | Cediranib 30 mg | RO4929097 20 mg |
|----------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|
| Diarrhoea| All 3–4         | 6 (86%)         | 0 (0%)          | 3 (43%)         | 0 (0%)          | 4 (66%)         |
| Hypertension| All 3–4 | 6 (86%)         | 2 (28%)         | 3 (43%)         | 0 (0%)          | 1 (17%)         |
| Fatigue | All 3–4         | 3 (43%)         | 3 (43%)         | 3 (43%)         | 0 (0%)          | 4 (66%)         |
| Nausea | All 3–4         | 3 (43%)         | 4 (57%)         | 3 (43%)         | 0 (0%)          | 4 (66%)         |
| Hypothyroidism | All 3–4 | 3 (43%)         | 2 (28%)         | 2 (28%)         | 0 (0%)          | 3 (50%)         |
| Headache | All 3–4        | 4 (57%)         | 1 (14%)         | 1 (14%)         | 0 (0%)          | 3 (66%)         |
| Hypophosphatemia | All 3–4 | 3 (43%)         | 2 (28%)         | 3 (43%)         | 0 (0%)          | 2 (33%)         |
| Increased ALT | All 3–4 | 2 (28%)         | 1 (14%)         | 3 (43%)         | 0 (0%)          | 3 (50%)         |
| Increased AST | All 3–4 | 0 (0%)          | 5 (71%)         | 2 (33%)         | 0 (0%)          | 2 (33%)         |

| Abbreviations: ALT = alanine aminotransferase; AST = aspartate aminotransferase. |

| Table 4. Pharmacokinetic parameters of RO4929097 at different DLs |
|-----------------|-------------------|-------------------|-------------------|
|                  | DL-1 (n: 5)       | DL-2 (n: 7)       | DL-3 (n: 5)       |
| Total RO4929097 | Day 1             | Day 10            | Day 22            | Day 1             | Day 10            | Day 22            | Day 1             | Day 10            | Day 22            |
| T\text{max, h}  | Median            | 2                 | 2                 | 2                 | 2                 | 2                 | 2                 | 2                 | 2                 |
| Range            | 1–2               | 1–4               | 1–24              | 0.5–24            | 0.5–24            | 1–24              | 0.5–6            | 0.5–4            | 1–2               |
| C\text{max, nmol l}^{-1} | Mean | 296.4             | 296               | 288.6             | 465.14            | 778.85            | 482               | 437.8             | 788.2             | 408               |
| s.d.             | 178.6             | 176.93            | 106.22            | 125.55            | 385.82            | 244.74            | 273.73           | 230.63           | 172.83            |
| AUC\text{t, ng h ml}^{-1} | Mean | 2678.07           | 3441.80           | 3547.46           | 5367.68           | 11237.66          | 6360.44           | 7467.97          | 12164.95          | 6085.72           |
| s.d.             | 1445.30           | 3025.29           | 1661.92           | 3374.58           | 7663.55           | 3919.95           | 5368.38          | 3688.61          | 2536.22           |

| Abbreviations: AUC = area under curve; DL = dose level. |

| Table 5. Pharmacokinetic parameters of cediranib at different DLs |
|-----------------|-------------------|-------------------|
| Cediranib       | DL-1 (cediranib = 20 mg) | DL-2 (cediranib = 20 mg) | DL-3 (cediranib = 30 mg) |
| T\text{max, h}  | Median            | 4                 | 2                 | 2                 |
| Range            | 2–6               | 2–6               | 1–4               |
| C\text{max, nmol l}^{-1} | Mean | 36.78             | 36.9              | 77.58             |
| s.d.             | 23.94             | 25.06             | 33.99             |
| AUC\text{t, ng h ml}^{-1} | Mean | 483.21            | 467.19            | 870.29            |
| s.d.             | 176.05            | 287.89            | 378.79            |

| Abbreviations: AUC = area under curve, DL = dose level. |
(Tolcher et al., 2012). Furthermore, the AUCt of RO4929097 on day 10 was higher than day 1 implying no CYP3A4 autoinduction at the dose range and schedule administered in this study (10–20 mg per day). A summary of the pharmacokinetic profile of both drugs at different DLs are represented in Tables 4 and 5 and Supplementary Appendix Figure A2.

It is important to mention that these analyses are limited, as only three DLs of combination therapy were studied.

**Antitumour activity.** Nineteen of the 20 patients enrolled on the study had at least one follow-up tumour assessment and were evaluable for objective response assessment. One partial response was observed. Eleven of the 19 evaluable patients (58%) had a best response of stable disease, whereas 7 (37%) patients had disease progression.

As of the data cut-off date on 6 November 2012, prolonged stable disease of ≥6 cycles was observed in 7 patients; 1 with uterine leiomyosarcoma received 15 cycles of treatment before disease progression, 2 with colorectal cancer (7 and 11 cycles), another 2 with renal cell carcinoma (11 and 13 cycles); 1 with cholangiocarcinoma who received 6 cycles of treatment and 1 patient with endometrial stromal sarcoma, a notably slow-growing low-grade malignancy, currently remains on study after 37 cycles of treatment and has achieved partial response after the data cut-off date (Figure 1).

**Pharmacodynamics.** We did not detect any correlation between the baseline values of circulating angiogenesis markers and time to treatment failure. Increases in VEGF-A, VEGF-C and SDF-1 were detected after dosing with cediranib, but there was no suggestion of relationship with dose or time to treatment failure (Figure 2).

No significant correlation was observed between expression of the three Notch pathway biomarkers evaluated (Jagged-1, Notch-3 receptor and NICD) and time to treatment failure (data not shown).

Mutational profiling was performed on DNA isolated from FFPE samples of 18 patients. Mutations were detected in samples of eight patients (Supplementary Appendix Table A2). None of

![Figure 1. Duration of exposure as of data cutoff date on 6 November 2012. *Patient continues on treatment. Abbreviation: DL, dose level.](image)

![Figure 2. Concentration of circulating angiogenic factors measured in the sera of patients during cycle 1 of treatment. (A) VEGF-A, (B) VEGF-C and (C) SDF-1. Increases in these factors were detected after dosing with cediranib, but there was no suggestion of relationship with dose or time to treatment failure.](image)
these mutations were Notch or angiogenesis pathway related and there was no correlation between mutational status and time to treatment failure.

**DISCUSSION**

This study demonstrated that a combination of RO4929097 with cediranib is tolerable in patients with advanced solid tumours. The RP2D was defined as 20 mg for RO4929097 on 3 days-on and 4 days-off schedule and 30 mg daily for cediranib. It is important to mention that RP2D was defined based on the available toxicity data from three doses that have been completed by the time this study was discontinued. Both agents could have potentially been escalated further if the study was carried out as per the initial protocol. Toxicities of this combination are similar to those observed with single agents in phase I clinical trials (Drevs et al., 2007; Tolcher et al., 2012). These non-life-threatening AEs were effectively addressed by dosing delay and dose reduction. They are also commonly observed in patients receiving cediranib and we saw no evidence of increased frequency or severity of these toxicities in the current study.

Preliminary evidence of antitumour activity were observed in some patients; 11 patients had stable disease and 1 patient with endometrial stromal sarcoma, a notably slow-growing low-grade malignancy, achieved partial response. Nine of them continued treatment for >4 cycles, most of whom had been heavily pretreated. There is a scientific rationale to target both Notch and VEGF signalling pathways and, hence, large number of prolonged disease stabilisation in this study may be a result of such effects.

The complexity of this combination approach underlines the importance of identifying suitable markers that can predict clinical benefit. In this study, we had planned testing of a large panel of the Notch and VEGF pathway components. However, after the decision of early study termination, we chose to test Jagged-1, Notch-3 receptor and NCID, which are overexpressed in multiple malignancies and associated with poor prognosis (Reedijk et al., 2007; Dickson et al., 2007; Lin et al., 2010; Wu et al., 2011). In future studies evaluating similar treatment strategies, it would be of great interest to assess the expression of DLL4, VEGFR1, VEGFR2 and VEGFR3, which are important components of cross-talk between VEGF and Notch pathways and tumour angiogenesis (Li et al., 2011). In our study, we did not detect association between the tested biomarkers of angiogenesis or the Notch pathway with treatment effect. However, these results are limited by the small number of treated patients and diversity of tumour types. Increases in VEGF and PI GF after dosing cediranib have been reported in monotherapy with cediranib and has been related to the antiangiogenic effect of the drug (Drevs et al., 2007). Similar patterns in levels of VEGF-A, VEGF-C and SDF-1 were detected in some of our patients. However, there was no correlation between these changes and time to treatment failure.

Overall, comparison of the RO4929097 and cediranib pharmacokinetic profile with historical monotherapy pharmacokinetic data at the same doses did not reveal any significant difference when they are administered in combination. As RO4929097 is highly bound in plasma to z1-acid glycoprotein and albumin, monitoring of unbound RO4929097 has been recommended particularly when it is administered with other compounds that may impact protein binding (Wu et al., 2012). The effect of protein binding on cediranib pharmacokinetics has not been reported. In the present study, we did not detect any significant alteration in the pharmacokinetic profile of the total and unbound RO4929097 when combined with cediranib. It should be mentioned that because of the study schedule, pharmacokinetic sampling was limited to 24 h after administration of RO4929097 and cediranib. Therefore, the elimination half-life and AUC0–t cannot be reliably calculated. Although the effect of RO4929097 on CYP3A4 induction has been shown in a previous phase I study of RO4929097 (Tolcher et al., 2012), no evidence of autoinduction was observed in the pharmacokinetic analysis on this study. One possibility is that in the present study, maximal daily dose of RO4929097 was only 20 mg and autoinduction is unlikely to occur at this low dose. Indeed, in the single agent phase I study of RO4929097, reversible CYP3A4 autoinduction was detected at daily doses above 24 mg in the 3 consecutive days per week schedule (Tolcher et al., 2012).

In conclusion, combination of RO4929097 and cediranib is well tolerated with no evidence to suggest a significant change in in the pharmacokinetics of these drugs. Preliminary evidence of anti-tumour efficacy with prolonged disease stabilisation in some patients with progressive malignancies warrants further clinical investigation of this treatment strategy. Unfortunately, because of the discontinuation of the RO4929097 and cediranib development programmes, further studies will need to occur with other agents that target Notch and VEGF pathways, respectively. A particularly interesting research strategy may be to inhibit Notch upon progression on an antiangiogenic agent in patients who had previously responded to the agent.

**ACKNOWLEDGEMENTS**

This study (PJC-004/CTEP 8503) is conducted by the Princess Margaret Hospital Phase I Consortium with support from the US National Cancer Institute U01 Cooperative Agreement Award (U01-CA132123).

**REFERENCES**

Allred DC, Harvey JM, Berardo M, Clark GM (1998) Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol 11: 155–168.

Batchelor TT, Duda DG, di Tomaso E, Ancukiewicz M, Plotkin SR, Gerstner E, Eichler AF, Drappatz J, Hochberg FH, Benner T, Louis DN, Cohen KS, Chea H, Exarhopoulos A, Loeffler JS, Moses MA, Ipy P, Sorensen AG, Wen PY, Jain RK (2010) Phase II evaluation of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma. J Clin Oncol 28: 2817–2823.

Benedito R, Rocha SF, Woeste M, Zamykal M, Radlke F, Casanovas O, Duarte A, Pytowski B, Adams RH (2012) Notch-dependent VEGFR3 upregulation allows angiogenesis without VEGF-VEGFR2 signalling. Nature 484: 110–114.

Campbell NP, Kunnavakkam R, Leigh N, Vincent MD, Gandara DR, Koczywas M, Gitlitz BJ, Agamah E, Thomas SP, Stadler WM, Vokes EE, Kindler HL (2012) Cediranib in patients with malignant mesothelioma: a phase II trial of the University of Chicago Phase II Consortium. Lung Cancer 78: 76–80.

Dickson BC, Mulligan AM, Zhang H, Lockwood G, O’Malley FP, Egan SE, Reedijk M (2007) High-level JAG1 mRNA and protein predict poor outcome in breast cancer. Mod Pathol 20: 685–693.

Drevs J, Siegert P, Medinger M, Mross K, Stecker R, Zirrgiebel U, Harder J, Blum H, Robertson J, Jurgensmeier JM, Puchalski TA, Young H, Saunders O, Unger C (2007) Phase I clinical study of AZD2171, an oral vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with advanced glioblastoma. J Clin Oncol 25: 3045–3054.

Dufraine J, Funahashi Y, Kitajewski J (2008) Notch signaling regulates tumor angiogenesis by diverse mechanisms. Oncogene 27: 5132–5137.

Goss G, Shepherd FA, Laurie S, Gauthier I, Leighl N, Chen E, Feld R, Powers J, Seymour L (2009) A phase I and pharmacokinetic study of daily oral cediranib, an inhibitor of vascular endothelial growth factor tyrosine kinases, in combination with cisplatin and gemcitabine in patients with advanced non-small cell lung cancer: a study of the National Cancer Institute of Canada Clinical Trials Group. Eur J Cancer 45: 782–788.
Phase I study of RO4929097 and cediranib

BRITISH JOURNAL OF CANCER

Goss GD, Arnold A, Shepherd FA, Dediu M, Ciuleanu TE, Fenton D, Zukin M, Walde D, Lamberge F, Vincent MD, Ellis PM, Laurie SA, Ding K, Frymire E, Gauthier I, Leigh NR, Ho C, Noble J, Lee CJ, Seymour L (2010) Randomized, double-blind trial of carboplatin and paclitaxel with either daily oral cediranib or placebo in advanced non-small-cell lung cancer: NCIC clinical trials group BR24 study. J Clin Oncol 28: 49–55.

Hoff PM, Hochhaus A, Pestalozzi BC, Tubbett NC, Li J, Kim TW, Koynov KD, Kurteva G, Pinter T, Cheng Y, van Eyll B, Pike L, Fielding A, Robertson JD, Saunders MP (2012) Cediranib plus FOLFLOX/CAPOX versus placebo plus FOLFLOX/CAPOX in patients with previously untreated metastatic colorectal cancer: a randomized, double-blind, phase III study (HORIZON II). J Clin Oncol 30: 3596–3603.

Jubb AM, Turley H, Moeller HC, Steers G, Russell AJ, Montgomery CP, Poulsom R, Harris AL (2006) Up-regulation of endothelial gamma-secretase cleavage of Notch-1. EMBO J 21: 5408–5416.

Patel NS, Dobbie MS, Rochester M, Steers G, Poulsom R, Le Monnier K, Cranston DW, Li JL, Harris AL (2006) Up-regulation of endothelial delta-like 4 expression correlates with vessel maturation in bladder cancer. Clin Cancer Res 12: 4836–4844.

Reedijk M, Olorcic S, Chang L, Zhang H, Miller N, McCready DR, Lockwood G, Egan SE (2005) High-level coexpression of Jag1 and NOTCH1 is observed in human breast cancer and is associated with poor overall survival. Cancer Res 65: 8530–8537.

Ridgway J, Zhang G, Wu Y, Stawicki S, Liang WC, Chanthary Y, Kowalski J, Watts RJ, Callahan C, Kasman I, Singh M, Chen M, Tan C, Hongo JA, De Sauvage F, Plowman G, Yan M (2006) Inhibition of DI4 signalling inhibits tumour growth by deregulating angiogenesis. Nature 444: 1083–1087.

Rizzo P, Osipo C, Foreman K, Golde T, Osborne B, Miele L (2008) Rational targeting of Notch signaling in cancer. Oncogene 27: 5124–5131.

Schmoll HJ, Cunningham D, Sobrero A, Karapetis CS, Rougier P, Koski SL, Kocakova I, Bondarenko I, Bodoky G, Mainwaring P, Salazar R, Barker P, Mookeree B, Robertson J, Van Cutsem E (2012) Cediranib with mFOLFOX6 versus bevacizumab with mFOLFOX6 as first-line treatment for patients with advanced colorectal cancer: a double-blind, randomized phase III study (HORIZON III). J Clin Oncol 30: 3588–3595.

Tien AC, Rajan A, Bellen HJ (2009) A Notch updated. J Cell Biol 184: 621–629.

Tolcher AW, Messersmith WA, Mikulska SM, Papadopoulos KP, Kwak EL, Gibbon DG, Patnaik A, Falchoux GS, Dasari A, Shapiro GI, Boylan JF, Xu ZX, Wang K, Koehler A, Song J, Middleton SA, Deutsch J, Demario M, Kurzrock R, Wheler JJ (2012) Phase I study of RO4929097, a gamma-secretase inhibitor of Notch signaling, in patients with refractory metastatic or locally advanced solid tumors. J Clin Oncol 30: 2348–2353.

Trarbach T, Schultheis B, Gauthier I, Schneider V, Strumberg D, Eberhardt WE, Le Scouiller S, Marotti M, Brown KH, Drevs J (2012) Phase I open-label study of cediranib, an oral inhibitor of VEGF signalling, in combination with the oral Src inhibitor saracatinib in patients with advanced solid tumours. Invest New Drugs 30: 1962–1971.

van Crijnsen H, Voest EE, Punt CJ, Hoekman K, Witteveen PO, Meijerink MR, Puchalski TA, Robertson J, Saunders O, Jurgensmeier JM, van Herpen CM, Giaccone G (2010) Phase I evaluation of cediranib, a selective VEGFR inhibitor signaling, in combination with gefitinib in patients with advanced tumours. Eur J Cancer 46: 901–911.

Wedge SR, Kendrew J, Hennequin LF, Valentine PJ, Barry ST, Kovak EL, Smith NR, James NH, Dukes M, Curwen JO, Chester R, Jackson JA, Bolivia S, Kilburn LL, Barnett S, Richmond GH, Wadsworth PF, Walker M, Bigley AL, Taylor ST, Cooper L, Beck S, Jurgensmeier JM, Ogilvie DJ (2005) AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer. Cancer Res 65: 4389–4400.

Wu J, Lorusso PM, Matherly LH, Li J (2012) Implications of plasma protein binding for pharmacokinetics and pharmacodynamics of the gamma-secretase inhibitor RO4929097. Clin Cancer Res 18: 2066–2079.

Wu K, Xu L, Zhang L, Liu Z, Hou J (2011) High Jagged1 expression predicts poor outcome in clear cell renal cell carcinoma. Ipn J Clin Oncol 41: 411–416.

Zhang W, Seymour L, Chen EX (2008) Determination of intact oxaliplatin in human plasma using high performance liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 876: 277–282.

This work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/

Supplementary Information accompanies this paper on British Journal of Cancer website (http://www.nature.com/bjc)